abstract | As critical regulators of numerous cell signaling pathways, tyrosine kinases are implicated in the pathogenesis of several diseases, including rheumatoid arthritis (rA). in the absence of disease, synoviocytes produce factors that provide nutrition and lubrication for the surrounding cartilage tissue; few cellular infiltrates are seen in the synovium. in rA, however, macrophages, neutrophils, T cells and B cells infiltrate the synovium and produce cytokines, chemokines and degradative enzymes that promote inflammation and joint destruction. in addition, the synovial lining expands owing to the proliferation of synoviocytes and infiltration of inflammatory cells to form a pannus, which invades the surrounding bone and cartilage. Many of these cell responses are regulated by tyrosine kinases that operate in specific signaling pathways, and inhibition of a number of these kinases might be expected to provide benefit in rA.
Introduction
rheumatoid arthritis (ra) is an autoimmune synovitis that affects 0.5% of the population and can result in disability owing to joint destruction. 1 a number of cellular responses are thought to be involved in the patho genesis of ra. an adaptive autoimmune response mediated by t cells and B cells is important in initiating the inflammatory cascade. macrophages, neutrophils, t cells and B cells migrate into synovial tissue, where they produce immune mediators and degradative molecules that break down the extra cellular matrix, in particular that of cartilage. synoviocytes undergo hyperplasia, and angiogenesis occurs, possibly to support the growth of the synovial lining. Finally, osteo clasts become activated and erode bone. the activation and function of the cell types involved in each of these processes depend on signaling through specific pathways, many of which involve protein tyrosine kinases (table 1, Figure 1 ). in support of an important role for tyrosine kinases in ra, proteins from the synovial tissue of ra patients have been found to be extensively phos phorylated by intracellular tyrosine kinases. 2 in this article, we discuss the experimental evidence that implicates specific tyrosine kinases in signal ing pathways that are central to the pathogenesis of ra, and address the potential to therapeutically target these kinases. owing to space limitations, we will not discuss other poten tial tyrosine kinase targets, including focal adhesion kinase, fibroblast growth factor receptor, epi dermal growth factor receptor, and discoidin receptor 2.
Tyrosine kinases
Cell surface and cytoplasmic tyrosine kinases tyrosine kinases control many fundamental cell processes, and comprise two general classes of molecules: receptor tyrosine kinases (rtKs) and nonreceptor tyrosine kinases (nonrtKs). 3 in addition to an extracellular ligandbinding domain and a membranespanning domain, rtKs usually possess an intracellular cytoplasmic domain that contains a kinase core and regulatory sequences. in the absence of ligands (growth factors, cytokines, etc.), rtKs are thought to exist in an equilibrium of monomers and dimers on the cell surface; ligand binding, however, increases the sta bility of dimers. typically, on dimerization, motifs within the intracellular portion of the receptor undergo autophos phorylation, which induces a conformational change that allows the receptor to bind atP and substrate. 3 the active kinase can then catalyze the transfer of the γ phosphate from atP to the hydroxyl groups of tyrosine residues on the receptor itself or on substrate proteins. tyrosine phos phorylation creates docking sites on the receptor for down stream signaling molecules or activates substrate proteins, both of which promote signal transduction ( Figure 2 ). 3 similarly, activation of nonrtKs, which lack ligand binding and transmembrane domains, occurs following phosphorylation of tyrosine residues on proteins by kinases within cytoplasmic complexes. as we will be discuss ing two members of the src kinase family-src and lck-we will use srcfamily kinases to outline nonrtK activa tion. members of the src family have six common struc tural regions, which, from the nterminal end, include a srchomology (sH)4 domain, a unique region, an sH3 domain, an sH2 domain, a catalytic domain (which com prises an nlobe and a Clobe), and a Cterminal tail. lipid moieties can attach to the sH4 domain to promote plasma membrane localization; the unique region of each family member mediates specific interactions with the cyto plasmic regions of rtKs and other nonrtKs; and the sH3 domain mediates interactions with target si gnaling molecules. the remaining domains, together with the sH3 reviews domain, modu late the activation of srcfamily kinases using two critical tyrosine residues-tyrosine 416 in the catalytic domain and tyrosine 527 in the Cterminal tail (the numbering refers to src)-with opposing effects. normally, srcfamily kinases reside in an inactive conforma tion, in which the molecule is folded upon itself such that the activation loop (which contains tyrosine 416) is buried between the two lobes of the catalytic domain. this folded configura tion is maintained by interactions between the sH3 domain and the linker region between the sH2 and catalytic domains, and by the binding of the sH2 domain to the Cterminal tail following phos phorylation of tyrosine 527. activation occurs when interactions between the sH2 and sH3 regions and high affinity binding ligands disrupt the intramolecular inter actions, allowing the molecule to unfold to expose tyrosine 416 on the activation loop for auto phosphorylation. Phosphorylation of this residue activates the kinase. 4 Inhibitors of tyrosine kinases a large number of smallmolecule tyrosine kinase inhibi tors (tKis) have been developed. these inhibitors typically, but not always, bind to the nucleotidebinding pocket of the catalytic domain, and can thereby modulate changes in the conformation of the molecule that are necessary for kinase activation. For instance, imatinib is a potent inhibi tor of several tyrosine kinases, including Kit (also known as CD117), plateletderived growth factor receptors α and β (PDGFrα and β), breakpoint cluster region (Bcr)-abelson murine leukemia viral oncogene homolog 1 (aBl1), colonystimulating factor 1 receptor (CsF1r), and leuko cytespecific protein tyrosine kinase (lck). imatinib blocks the function of Bcr-aBl, and possibly these other tyrosine kinases, by stabilizing their inactive conformation. 5 
FLS hyperplasia
ra is characterized by hyperplasia of the synovial lining. 1 synovial tissues derived from ra patients exhibit a marked increase in the number of macrophagelike and fibroblastlike synoviocytes (Flss). 1, 6 Key points rheumatoid arthritis (rA) is characterized by leukocyte infiltration, synoviocyte ■ hyperplasia and osteoclastogenesis, and tyrosine kinases have key roles in the signaling pathways that regulate these processes inhibition of platelet-derived growth factor receptors, vascular endothelial ■ growth factor receptors and Tie receptors might reduce synovial hyperplasia and angiogenesis inhibition of colony-stimulating factor receptor-1 and src might reduce ■ monocyte maturation and osteoclastogenesis
Blocking signaling through Bruton's tyrosine kinase might reduce B-cell ■ and T-cell activation Blocking KiT activation might induce mast cell apoptosis, thereby reducing the ■ production of inflammatory cytokines and degradative molecules in the synovium imatinib, which inhibits several tyrosine kinases, and more-specific inhibitors ■ of Janus kinases and syk, have already shown efficacy in the treatment of rA; however, toxicity remains an issue
PDgFrs in FlS proliferation
Key molecules that are involved in Fls proliferation are PDGFrs, of which there are two (PDGFrα and β), 7 and their ligands, which are dimers formed from PDGFs a-D. 2, 8 increased levels of PDGFrα transcripts and proteins are seen in Flss cultured from ra patients compared with those taken from control patients; PDGFrβ is expressed on stromal cells in the synovial lining, and in smooth muscle cells and capillary cells in ra synovium (table 1) . [8] [9] [10] PDgFrs as potential targets In vitro, PDGF induces proliferation of synovial fibro blasts derived from patients with ra more potently than synovial fibroblasts derived from healthy individuals. 9 in rodent models of ra, imatinib reduced the severity of symptoms when administered before the development of the disease and inhibited disease progression when given to mice that had already developed the disease. [11] [12] [13] in addition, nilotinib, which inhibits Bcr-aBl, PDGFrα and β and Kit, was effective in treating arthritis in the K/Bxn seruminduced model (C. D' aura swanson et al., unpublished data). the efficacy of imatinib (and nilo tinib) in models of arthritis is probably attributable, at least in part, to inhibition of PDGFr, as several groups have shown that imatinib inhibits the proliferation of Flss from ra patients by blocking the phosphorylation of PDGFr and the activation of downstream mediators of the PDGFr signaling pathway.
14,15 evidence to date, there fore, indicates that PDGFrα and β have a central role in the proliferation of Flss, and thereby represent potential therapeutic targets in ra.
Angiogenesis vascular density is higher in the synovia of patients with ra and osteoarthritis (oa) than in healthy synovium. 16 increased vascularity might support the growth of the synovial lining, so inhibiting angiogenesis is an attrac tive therapeutic approach for the treatment of arthritis. such inhibition might be achieved by targeting vascular endothelial growth factor receptors 1 and 2 (veGFr1 and 2) and tie1 and tie2 (also known as teK).
VegFs and VegFrs as potential targets veGFrs comprise the moststudied family of rtKs in ra. the family includes veGFr1 (also known as Flt1 or Flk2), veGFr2 (known as KDr in humans and Flk1 in mice), veGFr3 (Flt4), and two receptors that lack kinase domains: neuropilin (nrP)1 and nrP2. 17 ligands for the veGFrs include veGFs a-F and placental growth factor. 17 several studies have demonstrated an increase in the expression of veGFa protein in the syno vial fluid, lymph, serum and synovial tissue of patients with ra. the levels of serum veGFa positively correlate with ra disease activity. [18] [19] [20] veGFa activates veGFr1 and veGFr2, which, in turn, induces endothelial cell prolifera tion, sprouting, migration and tube formation, thereby promoting the generation of blood vessels. 17 veGFa also supports osteoclastogenesis by mimicking the actions reviews of macrophage colonystimulating factor (mCsF; also known as CsF1). 17, 21 Certain veGFa isoforms and nrP1 induce the upregulation in synoviocytes of Bcell leukemia/ lymphoma 2 (Bcl2), which can protect the cells against apoptosis and thereby promote hyperplasia. 22 veGFC and veGFD increase vascular permeability and angiogenesis by signaling through veGFr2. 17 veGFC is present in many cells in the thickened synovial lining in ra, espe cially in blood vessel pericytes and smooth muscle cells. 23 endothelial cells, monocytes/macrophages and osteoblasts in the synovial tissue of ra patients express veGFr1 (table 1), but the levels of this protein do not correlate with vascularity. 17, 24, 25 veGFr2 can be detected in endothelial cells, especially in small blood vessels in pannus tissue, and its expression is upregulated in the synovial tissue of ra patients compared to that of oa patients (table 1) . 22, 23, 25 several groups have shown that inhibition of veGFa or veGFr1 delays the onset and reduces the severity of murine arthritis. [26] [27] [28] [29] veGFr2 is thought to mediate veGFainduced endothelial cell migration and prolifera tion, but the value of inhibiting veGFr2 or veGFr3 in arthritis models remains unclear. 17 inhibition of veGFr2 has yielded mixed results, whereas panveGF inhibitors have shown only moderate efficacy. 26, 28, 29 sorafenib, which inhibits multiple tyrosine kinases, including veGFr2 and veGFr3, showed moderate therapeutic efficacy against murine K/Bxn seruminduced arthritis, but failed to reduce disease scores or paw swelling in murine collagen induced arthritis (Cia) (C. D' aura swanson et al., unpub lished data). sunitinib, which inhibits veGFr1, veGFr2 and veGFr3, as well as several other kinases, 30 reduced the incidence and severity of both K/Bxn seruminduced arthritis and Cia (C. D' aura swanson et al., unpublished data). However, because sorafenib and sunitinib inhibit more than one form of veGFr, morespecific inhibi tors or genetic manipulation of the individual veGFrs is required to determine the importance of the different veGFrs in arthritis models; thus, further research is needed to clarify the roles of individual veGFrs in ra. nevertheless, findings to date indicate that veGFr1 and veGFa are prime candidates for therapeutic intervention in ra.
tIe1 and tIe2 as potential targets the rtKs tie1 and tie2 regulate angiogenesis and are expressed on endothelial cells. 31 their ligands are the angiopoietins 1-4:
31 angiopoietin 1 is a potent tie2 agonist, angiopoietin 2 can function as a tie2 agonist or antagonist , depending on cell context, and tie1 regulates tie2 activity . 31 tie1, tie2, angiopoietin 1 and reviews angiopoietin 2 are all expressed in synovial tissue from ra patients, 32, 33 and inhibition of tie1 or tie2 signaling was shown to be beneficial in Cia (table 1) . adenovirus mediated overexpression of a soluble form of tie2, which functions as an antagonist of tie2 signaling, significantly decreased disease incidence and severity in a Cia model; these results were associated with a reduction in angio genesis, synovial cell infiltration and radiographic paw scores. 34 tie1751, a naturally occurring splice variant of tie1, also reduced arthritis severity in Cia.
28 tie1 and tie2, therefore, represent potential targets in ra therapy.
T-cell and B-cell activation the importance of t cells and B cells in the patho genesis of ra is underscored by several findings: the genetic linkage of ra to Hla genes; the association of ra with autoanti bodies; the success of a fusion protein that inhibits tcell costimulation (Ctla4-ig; abatacept) in an ra clinical trial; and the efficacy of Bcell depletion by rituximab in the treatment of ra patients. 35, 36 Kinase involvement activation of t cells and B cells through tcell recep tors (tCrs) and Bcell receptors (BCrs), respectively, requires a variety of tyrosine kinases, including lck, spleen tyrosine kinase (syk), and Bruton's tyrosine kinase (Btk). 37 inhibition of lck disrupts tCr signaling, and thereby reduces tcell activation, proliferation, and cytokine pro duction. 38 Btk is primarily expressed in B cells, mast cells, platelets and myeloid cells. 39 (table 2) . 39, 41 Preventive treatment with dasatinib, which potently inhibits lck and Btk in addition to other tyrosine kinases, 42 reduced the incidence and severity of both Cia and K/Bxn seruminduced arthritis (C. D' aura swanson et al., unpublished data). syk will be discussed in further detail below.
Mast cells
activation and function mast cells produce factors that regulate a number of func tions, including lymphocyte migration, angio genesis, inflammation, and cartilage and bone destruction. 43 ,44 mast cells enhance vascular permeability through the release of bradykinin, and produce leukotriene B4, which might recruit CD8 + effector cells. 43, 44 through the production of heparin, basic fibroblast growth factor, tumor necro sis factor (tnF), interleukin (il)13, il1β, il8, veGF and PDGF, mast cells promote angiogenesis; by produc ing tryptase, chymase, histamine and receptor activator for nuclear factor κB ligand (ranKl; also known as tnF ligand superfamily, member 11), these cells also promote the destruction of extracellular matrix and bone. 43 ,44 mast cells constitute up to 3% of cells in healthy synovium, but this figure can increase to 5% in murine and human arthritic synovial tissue. 43, 44 in the synovial tissue of ra patients, mast cells are observed at the cartilage-pannus junction, near blood vessels, and in areas of fibrosis. 44 molecules that inhibit mast cell degranulation decrease joint swelling in murine models of arthritis; 44 w/wv mice, which are deficient in mast cells, are resistant to K/Bxn seruminduced arthritis. 45 targeting KIt signaling through Fcεri, Fcγriii, Kit and complement receptors probably activates mast cells in ra. 43, 44 Because mast cell activation can occur through several distinct signaling pathways, blocking this activation can be chal lenging. one strategy to reduce the production of mast cell effector molecules is to induce apoptosis in these cells; indeed, imatinib has been shown to reduce the number of cultured mast cells via apoptosis. 46 the Kit ligand (also known as stemcell factor [sCF] ) is thought to be one of the most important growth factors for mast cells. 43 M-CsF, macrophage colony-stimulating factor; MMP , matrix metalloproteinase; PDGFr, platelet-derived growth factor receptor; rANKL, receptor activator for nuclear factor κB ligand; sCF, stem cell factor; TNF, tumor necrosis factor. reviews is found in increased quantities in the synovial fluid of ra patients compared to that of oa patients, 47 is expressed on multiple cells in the synovium, 48 and induces a strong chemotactic response in mast cells from ra patients. 49 Kit represents, therefore, a logical target for ra therapy, especially given its restricted expression in mast cells.
Osteoclast-mediated destruction
osteoclasts erode periarticular bone in ra. 21 their forma tion from monocytes and dendritic cells is regulated by ranKl and mCsF. monocytes from synovial fluid from the joints of ra patients form large, multi nucleated, tartrateresistant and acid phosphatasepositive cells (which is indicative of the presence of osteoclasts) on culture with mCsF and ranKl. 50 mCsF, through its ability to induce Bcl2 and activate rasrelated C3 botu linum toxin substrate 1, also promotes osteoclast survival and the formation of resorptive pits.
21
CSF1r as a potential target mCsF and its receptor CsF1r (a product of the fms gene) are expressed in the synovium of ra patients. CsF1r protein expression is observed in the synovial lining layer (predominantly on CD68 + macrophages) and around vessels in the sublining, as well as in osteoclasts (table 1) . 51 endothelial cells and fibroblasts from ra patients express high levels of mCsF, 52 and mCsF levels are increased in synovial tissues and fluid derived from ra patients. 53 Findings from rodent models of arthritis indicate that mCsF and CsF1r have crucial roles in disease patho genesis and progression. mCsF exacerbates arthritis induced by submaximal levels of collagen or methylated bovine serum albumin in mice, 54, 55 and in rat arthritis. 56 mice deficient in mCsF (op/op mice) are resistant to the develop ment of arthritis, 57 whereas antibodies against mCsF reduced the clinical severity of Cia, 54 and neu tralizing antibodies targeting CsF1r inhibited inflam matory osteolysis. 58 Furthermore, the small molecule CsF1r inhibitors Gw2580 (GlaxosmithKline, uxbridge, uK) and Ki20227 (Kirin Pharma Company ltd, takasaki, Japan) show therapeutic efficacy in rodent models of arthritis. 59, 60 several pharmaceutical companies are develop ing CsF1rspecific inhibitors.
Src as a potential target src is a ubiquitously expressed nonrtK that is acti vated, among other means, by binding to protein tyrosine kinase 2β (PtK2β; also known as Pyk2) following inte grin activation. 61 integrins, such as α v β 3 , are critical for bone resorption, as they are thought to mediate macro phage and osteoclast migration and osteoclast adhesion to bone, 62 and they promote osteoclast survival. 63 src is also important in ranK signaling, as interaction of src with tnF receptorassociated factor 6 (traF6) follow ing ranK receptor engagement leads to the phospho rylation of downstream signaling molecules. 64 in ra patients, cells of the synovial lining and subsynovial macrophages express phosphorylated (activated) src. 65 targeted disruption of src in mice induces osteopetrosis, which is characterized by decreased bone resorption. 62 in addition, overexpression in vivo of Cterminal src kinase (Csk), which negatively regulates src and other srcfamily kinases, reduced the expression of these kinases and decreased arthritis severity in rats. 66 Chemokine and cytokine production tnF and il1 have key roles in ra as evidenced by the efficacy of inhibitors of both of these molecules in the treatment of ra. 67, 68 moreover, tnF and il1 signaling pathways can synergize with, or activate, tyrosine kinases. specifically, PDGF can synergize with il1 and tnF to promote fibroblast proliferation and prosta glandin e2 production. 69 similarly, il1 and tnF stimulate the pro duction of mCsF by cartilage and fibroblasts. 70 Blockade of tnF and il1 might, therefore, provide benefit in ra 3 The active kinase catalyzes the transfer of γ-phosphate from ATP to hydroxyl groups of tyrosine residues on the receptor itself or on substrate proteins, creating binding sites or activating substrate proteins, respectively, to promote signal transduction. b | src-family kinases normally adopt an inactive conformation: the molecule is folded upon itself, such that the activation loop, containing tyrosine 416, is buried between the N-lobe and C-lobe of the kinase domain. This configuration is maintained by interactions between the sH3 domain and the linker region connecting the sH2 with the catalytic domain, and by binding of the sH2 domain to the C-terminal tail following phosphorylation of tyrosine 527. Activation occurs when interactions between the sH2 and sH3 regions and highaffinity binding ligands disrupt these intramolecular interactions, allowing unfolding and revealing tyrosine 416 for autophosphorylation. The mechanism of src activation is outlined here. Abbreviations: L, ligand; rTK, receptor tyrosine kinase; sH2, sH3 and sH4, src-homology 2, 3 and 4 domains; Ur, unique region. reviews by reducing the production of synovial mCsF and effects of PDGF.
TKIs and RA eight smallmolecule tKis have so far been approved by the FDa for the treatment of different types of cancer; five of these tKis might provide benefit in the treatment of ra (table 2) . several tKis are also in clinical develop ment for the treatment of ra (table 2) . a number of case reports and a small case series indicate that imatinib, which is approved for the treatment of cancer, might provide benefit in ra and other inflammatory diseases. these reports include studies involving patients with longstanding ra who developed Bcr-aBlpositive chronic mye logenous leukemia 71 or Kitpositive gastro intestinal stromal tumor. 72 these patients received ima tinib (300-400 mg daily) for their malignancy and showed improvement in ra symptoms, as reflected by reductions in the levels of inflammatory markers and improvements in disease activity indices. 72 on the basis of these results, eklund and Joensuu 72 administered openlabel imatinib treatment to three patients who had treatmentrefractory ra. all three patients experienced some degree of clini cal improvement, as assessed by measurement of inflam matory markers and swollen and tender joint counts; however, one patient discontinued therapy owing to the development of a rash. 72 inhibitors that target other tyrosine kinases with potential involvement in ra, such as members of the Janus kinase (JaK) family 73 77 have under gone or are currently undergoing phase ii clinical trials for the treatment of this disease (table 2) . the syk inhibi tor fostamatinib disodium showed significant improve ments in aCr response and 28joint disease activity score (Das28) in a phase ii study. 77 nevertheless, the use of syk inhibitors might be limited by toxicityrelated adverse effects that result in hepatic inflammation and hypertension. it remains unclear whether these toxicities are the result of a class effect or a molecule effect. 77 
Conclusions
scientists and clinical researchers have begun to investi gate smallmolecule tKis as a novel therapeutic approach to ra and other inflammatory diseases. of the tyrosine kinases discussed in this review, those that currently show the greatest potential as therapeutic targets in ra are CsF1r and Kit. the expression of these kinases is restricted to specific cell types within the synovium, and cumulative evidence from studies on tissues from ra patients and from animal models, as well as the efficacy of imatinib in treating ra, point to a central role for CsF1r and Kit in ra pathogenesis. However, as our knowledge regarding the roles of other tyrosine kinases in ra increases, their importance as targets might also be fully appreciated.
In vitro and in vivo observations involving both rodent models and samples derived from ra patients indicate that targeting the kinases discussed herein might provide benefit in the treatment of ra. However, several issues remain. First, although each of these molecules seems to have an important role in the pathogenesis of ra, their Abbreviations: Bcr-ABL, breakpoint cluster region-Abelson; CML, chronic myelogenous leukemia; CsF1r, colony-stimulating factor-1 receptor; DDr, discoidin domain receptor; FAK, focal adhesion kinase; JAK, Janus kinase; GisT, gastrointestinal stromal tumor; NA, not applicable; PDGF, platelet-derived growth factor; rA, rheumatoid arthritis; veGFr, vascular endothelial growth factor receptor.
reviews relative contributions need to be further defined. second, the therapeutic effect (or lack thereof) of tKis in animal models cannot reliably be extrapolated to human ra patients. 78 third, tKis such as imatinib and dasatinib are pleiotropic inhibitors-they might additionally inhibit tyrosine kinases that are not involved in ra, and thus be more likely to cause unrelated tissue damage. tyrosine kinases have central roles in many physiologic processes: for example, PDGFr regulates fibroblast proliferation and wound healing, 79 and CsF1r regulates monocyte lineage cell survival and differen tiation. 80 smallmolecule tKis will partly block several of these physiologic responses, and might thereby cause targetbased toxicities that limit their therapeutic use, as illustrated by recent clinical trials involving syk inhibitors. 77 it is difficult to fully anticipate the toxicities and therapeutic benefits that might arise from the inhibition of a particular tyrosine kinase or set of tyrosine kinases.
although we focus on smallmolecule inhibitors in this review, other methods exist to target tyrosine kinases in ra. For example, antibodies targeting the extracellular domains of rtKs could compete with ligand binding or interfere with the adoption of molecular conformations necessary for activation. in addition, small interfering rnas might be used to downregulate the expression of specific tyrosine kinases. specific targeting of tyrosine kinases that have central roles in the pathogenesis of ra will need to be carried out in clinical trials. the severity of disease and the adverse effects of a given tKi must be carefully con sidered. Given the breadth of therapeutics that are already available for the treatment of ra, it will be essential to identify tKis with therapeutic indices that are sufficient for their use in ra.
Review criteria
PubMed was searched in November 2008 using the following PubMed terms, alone and in combination, to identify original articles in the literature, published in english, on tyrosine kinases in rheumatoid arthritis: "rheumatoid arthritis", "tyrosine kinase", "imatinib", "sorafenib", "sunitinib", "dasatinib", "nilotinib", "syk", "JAK", "PDGF", "veGF", "Tie", "src", "KiT", and "M-CsF". we cited data frequently from primary studies, but also included information from reviews, conference abstracts and press releases.
